Abstract
Several possible mechanisms for the synergistic anti-tumour effects between tumour necrosis factor alpha (TNF-α) and melphalan after isolated limb perfusion (ILP) have been presented. We found a significant sixfold increase in melphalan tumour tissue concentration after ILP when TNF-α was added to the perfusate, which provides a straightforward explanation for the observed synergism between melphalan and TNF-α in ILP. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Alexander HR, Brown CK, Bartlett DL, Libutti SK, Figg WD, Raje S and Turner E (1998) Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms. Clin Cancer Res 4: 2357–2362
De Boeck G, van Cauwenberghe K, Eggermont AMM, van Oosterom AT and de Bruijn EA (1997) Determination of melphalan and hydrolysis products in body fluids by GC-MS. J High Res Chromat 20: 697–700
Borel Rinkes IHM, de Vries MR, Jonker AM, Swaak TJG, Hack CE, Nooijen PTGA, Wiggers T and Eggermont AMM (1997) Isolated hepatic perfusion in the pig with TNF-α with and without melphalan. Br J Cancer 75: 1447–1453
Eggermont AMM, Schraffordt Koops H, Liénard D, Kroon BBR, van Geel AN, Hoekstra HJ and Lejeune FJ (1996 a) Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for non-resectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 14: 2653–2665
Eggermont AMM, Schraffordt Koops H, Klausner J, Kroon BBR, Schlag PM, Liénard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector JC and Lejeune FJ (1996 b) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: the cumulative multicenter european experience. Ann Surg 224: 756–765
Fajardo LF, Kwan HH, Kowalski J, Prionas SD and Allison AC (1992) Dual role of tumor necrosis factor-α in angiogenesis. Am J Pathol 140: 539–544
Folli S, Pelegrin A, Chalandon Y, Yao X, Buchegger F, Lienard D, Lejeune FJ and Mach JP (1993) Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 53: 829–836
Klaase JM, Kroon BBR, Benckhuijsen C, van Geel AN, Albus-Lutter CE and Wieberdink J (1989) Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 64: 616–621
Kristensen CA, Nozue M, Boucher Y and Jain RK (1996) Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br J Cancer 74: 533–536
Liénard D, Ewalenko P, Delmotte JJ, Renard N and Lejeune FJ (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10: 52–60
Manusama ER, Nooijen PTGA, Stavast J, Durante NMC, Marquet RL and Eggermont AMM (1996) Synergistic antitumour effect of recombinant human tumour necrosis factor α with melphalan in isolated limb perfusion in the rat. Br J Surg 83: 551–555
Manusama ER, Nooijen PTGA, Stavast J, de Wilt JHW, Marquet RL and Eggermont AMM (1998) Assessment of the role of neutrophils on the antitumor effect of TNF-α in an in vivo isolated limb perfusion model in sarcoma-bearing brown Norway rats. J Surg Res 78: 169–175
Maruo Y, Konno H and Baba S (1992) Therapeutic effects of liposomal adriamycin in combination with tumor necrosis factor-α. J Surg Oncol 49: 20–24
Nooijen PTGA, Manusama ER, Eggermont AMM, Schalkwijk L, Stavast J, Marquet RL, de Waal RMW and Ruiter DJ (1996) Synergistic antitumour effects of TNF-α and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathologic, immunohistochemical and electron microscopic study. Br J Cancer 74: 1908–1915
Pogrebniak HW, Witt CJ, Terrill R, Kranda K, Travis WD, Rosenberg SA and Pass HI (1994) Isolated lung perfusion with tumor necrosis factor: a swine model in preparation of human trials. Ann Thorac Surg 57: 1477–1483
Posner M, Liénard D, Lejeune FJ, Rosenfelder D and Kirkwood J (1994) Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor alpha (TNF) alone for metastatic in-transit melanoma. Proc Annu Meet Am Soc Clin Oncol 13: A1351
Renard N, Liénard D, Lespagnard L, Eggermont AMM, Heimann R and Lejeune FJ (1994) Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNFα). Int J Cancer 57: 656–663
Renard N, Nooijen PTGA, Schalkwijk L, de Waal RMW, Eggermont AMM, Liénard D, Kroon BBR, Lejeune FJ and Ruiter DJ (1995) VWF release and platelet aggregation in human melanoma after perfusion with TNFα. J Pathol 176: 279–287
Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P and Lejeune FJ (1998) Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 4: 408–414
Shimomura K, Manda T, Mukumoto S, Kobayashi K, Nakano K and Mori J (1988) Recombinant human tumor necrosis factor-α: thrombus formation is a cause of anti-tumor activity. Int J Cancer 41: 243–247
Suzuki S, Ohta S, Takashio K, Nitanai H and Hashimoto Y (1990) Augmentation for intratumoral accumulation and anti-tumor activity of liposome-encapsulated adriamycin by tumor necrosis factor-alpha in mice. Int J Cancer 15: 1095–1100
Umeno H, Watanabe N, Yamauchi N, Tsuji N and Okamoto T and Niitsu (1994) Enhancement of blood stasis and vascular permeability in Meth-A tumors by administration of hyperthermia in combination with tumor necrosis factor. Jpn J Cancer Res 85: 325–330
Van der Veen AH, Durante NMC, Breurs J, Nooijen PTGA, Marquet RL and Eggermont AMM (1999) In vivo isolated kidney perfusion with TNF-α in tumour bearing rats. Br J Cancer 79: 433–439
de Wilt JHW, Manusama ER, van Tiel ST, van IJken MGA, ten Hagen TLM and Eggermont AMM (1999) Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 80: 161–166
Yi E and Ulich T (1992) Endotoxin, interleukin-1, and tumor necrosis factor cause neutrophil-dependent microvascular leakage in postcapillary venules. Am J Pathol 140: 659–663
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
de Wilt, J., ten Hagen, T., de Boeck, G. et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 82, 1000–1003 (2000). https://doi.org/10.1054/bjoc.1999.1032
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.1032
Keywords
This article is cited by
-
Neoadjuvant Treatment of Locally Advanced Soft Tissue Sarcoma of the Extremities to Avoid Amputation. Isolated Limb Perfusion is a Valid Option
Hellenic Journal of Surgery (2019)
-
Stellenwert der isolierten Extremitätenperfusion bei Sarkomen
Der Onkologe (2018)
-
Läsionale Therapieoptionen beim maligen Melanom
Der Onkologe (2018)
-
TNF-alpha and melphalan-based isolated limb perfusion: no evidence supporting the early destruction of tumour vasculature
British Journal of Cancer (2015)
-
Peptide-Mediated Targeting of Cytokines to Tumor Vasculature: The NGR-hTNF Example
BioDrugs (2013)